Compass Financial Management LLC Buys Shares of 600,230 Actinium Pharmaceuticals, Inc. $ATNM

Compass Financial Management LLC purchased a new position in Actinium Pharmaceuticals, Inc. (NYSE:ATNM) in the second quarter, Holdings Channel reports. The fund purchased 600,230 shares of the company’s stock, valued at approximately $588,000.

Several other institutional investors have also made changes to their positions in ATNM. Vanguard Group Inc. grew its position in Actinium Pharmaceuticals by 0.9% during the third quarter. Vanguard Group Inc. now owns 1,384,543 shares of the company’s stock valued at $2,215,000 after purchasing an additional 12,703 shares in the last quarter. AM Investment Strategies LLC purchased a new stake in Actinium Pharmaceuticals in the 4th quarter worth approximately $40,000. Bank of America Corp DE boosted its stake in shares of Actinium Pharmaceuticals by 76.6% during the 4th quarter. Bank of America Corp DE now owns 78,767 shares of the company’s stock valued at $99,000 after buying an additional 34,176 shares during the period. AQR Capital Management LLC boosted its stake in shares of Actinium Pharmaceuticals by 278.6% during the 1st quarter. AQR Capital Management LLC now owns 63,249 shares of the company’s stock valued at $102,000 after buying an additional 46,545 shares during the period. Finally, Qube Research & Technologies Ltd purchased a new position in shares of Actinium Pharmaceuticals during the 2nd quarter valued at $70,000. 27.50% of the stock is currently owned by institutional investors and hedge funds.

Actinium Pharmaceuticals Stock Performance

NYSE ATNM opened at $1.10 on Monday. Actinium Pharmaceuticals, Inc. has a 1-year low of $0.74 and a 1-year high of $1.81. The firm’s fifty day simple moving average is $0.94 and its 200-day simple moving average is $1.08. The company has a market capitalization of $34.59 million, a PE ratio of -0.79 and a beta of 0.01.

Actinium Pharmaceuticals Profile

Actinium Pharmaceuticals, Inc is a clinical-stage biotechnology company focused on the development of targeted radiopharmaceutical therapies for patients with hematologic malignancies. The company’s proprietary technology platform combines monoclonal antibodies with radioisotopes to deliver highly potent, cell?killing radiation directly to cancer cells while sparing healthy tissues. Actinium’s lead product candidate, Iomab?B, is being evaluated as a conditioning regimen for older patients with acute myeloid leukemia (AML) who are ineligible for standard bone marrow transplants.

In addition to Iomab?B, Actinium’s pipeline includes Actimab?A, an anti?CD33 antibody labeled with the radioisotope bismuth?213 for the treatment of relapsed or refractory AML.